Hdl Acceptors
Hdl Acceptors - Related Videos
08:24
Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation
0 Views •
Cited by 4 •
2017
Simple homogenization was used to prepare novel, high-density, lipoprotein-mimicking nanoparticles to encapsulate nerve growth factor. Challenges, detailed protocols for nanoparticle preparation, in vitro characterization, and in vivo studies are described in this article.
09:57
18F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor (SiFA) for Positron Emission Tomography
0 Views •
Cited by 3 •
2020
The synthesis of fluorine-18 (18F) labeled radiopharmaceuticals for positron emission tomography typically requires months of experience. When incorporated into a radiotracer, the silicon-fluoride acceptor (SiFA) motif enables a simple 18F-labeling protocol that is independent of costly equipment and preparatory training, while reducing precursor quantity needed and utilizing milder reaction conditions.
09:48
Fast and Simplified Method for High Through-put Isolation of miRNA from Highly Purified High Density Lipoprotein
0 Views •
Cited by 2 •
2016
MicroRNAs play an important regulatory role and are emerging as novel therapeutic targets for various human diseases. It has been shown that miRNAs are carried in high density lipoproteins. We have developed a simplified method to rapidly isolate purified HDL suitable for miRNA analysis from human plasma.
10:39
Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification
0 Views •
Cited by 40 •
2016
This protocol describes the isolation and quantification of high-density lipoprotein small RNAs.
03:06
Encapsulating Nerve Growth Factor in High-Density Lipoprotein-Mimicking Nanoparticles
0 Views •
2025
Source: Zhu, J., et. al., Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation. J. Vis. Exp. (2017)This video demonstrates the stepwise assembly of NGF-loaded HDL-mimicking nanoparticles using protamine-assisted encapsulation and lipid-based self-assembly for potential neurotrophic delivery applications.
FAQs
ABCA1 and ABCG1 provide cellular routes for transferring excess cholesterol and phospholipids to HDL-related acceptors. Their activity influences how much lipid a cell can release for subsequent processing. Studying these transporter-dependent steps helps investigators connect cellular lipid handling with reverse cholesterol transport, rather than treating HDL as only a circulating concentration.
LCAT converts free cholesterol into cholesteryl esters after lipid transfer occurs. This chemical change allows the esterified cholesterol to move into the lipoprotein core, supporting continued lipid processing within the particle. Including this step in mechanistic studies helps explain how initially surface-associated cholesterol is handled during reverse cholesterol transport.
HDL concentration indicates how much HDL is present, whereas acceptor capacity evaluates how effectively the particles or apolipoprotein A-I complexes can receive excess cellular lipids. These measurements therefore describe different features of lipid handling. Comparing them can provide a broader assessment of reverse cholesterol transport and may add information relevant to cardiovascular risk.
These assays help investigate reverse cholesterol transport, the pathway through which excess cellular cholesterol is directed toward HDL-mediated clearance. They can also support broader studies of lipid metabolism by examining how cellular efflux, lipid acceptance, and cholesterol esterification relate to one another. The resulting measurements are useful for connecting molecular events with lipid homeostasis.
HDL acceptor measurements are used to study processes associated with atherosclerosis and cardiovascular risk. Because the assay focuses on functional lipid acceptance rather than HDL amount alone, it can help researchers evaluate whether cholesterol clearance mechanisms are operating effectively. This makes acceptor capacity a useful research measure when investigating cardiovascular biology and lipid homeostasis.
Therapy studies can use HDL acceptor capacity to examine whether an intervention improves the handling and clearance of excess cholesterol. The measurement provides a functional perspective on reverse cholesterol transport, complementing HDL concentration data. It is therefore relevant to research on treatments intended to enhance cholesterol clearance and to determine how such approaches affect lipid metabolism or atherosclerosis-related processes.